| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Gross Margin | 66.97% | 78.76% | 31.17% | 40.67% | 45.18% | 32.44% |
| Operating Margin | -1942.20% | -690.72% | -2966.01% | -1476.51% | -1336.60% | -67.12% |
| EBITDA Margin | -1875.48% | -661.45% | -2867.28% | -1476.51% | -1336.60% | -67.12% |
| Net Margin | -1893.58% | -667.77% | -3020.17% | -1541.33% | -1305.13% | -66.10% |
| Current Ratio | 1.33 | 7.60 | 1.50 | 4.17 | 13.06 | 0.48 |
| Quick Ratio | 1.33 | 7.60 | 1.50 | 4.17 | 13.06 | 0.48 |
| Debt / Equity | — | — | — | — | — | 0.16 |
| ROE | -400.07% | -72.98% | -317.65% | -91.86% | -45.51% | -190.14% |
| ROA | -221.26% | -62.50% | -177.29% | -68.71% | -39.86% | -40.27% |
| Asset Turnover | 0.12 | 0.09 | 0.06 | 0.04 | 0.03 | 0.61 |
| Book Value / Share | 0.00 | 0.00 | 0.31 | 0.98 | 1.98 | 0.12 |
Longeveron Inc. is a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. Its lead investigational product, Lomecel-B (also known as laromestrocel), is an allogeneic mesenchymal stem cell formulation derived from the bone marrow of young, healthy adult donors. This therapy promotes tissue repair, regeneration, reduces inflammation, and supports healing through multiple mechanisms of action. Longeveron Inc. focuses on key pipeline indications including hypoplastic left heart syndrome, a rare pediatric heart condition; Alzheimer's disease; and aging frailty. The company advances these programs through ongoing Phase 2 clinical trials and has received FDA designations to support development. Operating in the regenerative medicine sector, Longeveron Inc. sources materials from established bone marrow suppliers and conducts research primarily in the United States, with activities extending to Japan. Founded in 2014 and headquartered in Miami, Florida, it plays a role in addressing unmet needs in chronic diseases affecting healthspan.